Policy on description of drug's manufacturing arouses concern in wholesaling industry

Published: 2003-01-17 06:57:00

Updated: 2003-01-17 06:57:00

The government plans to make a thorough inspection on the description of manufacturing and lot numbers of drugs in the on-spot process of KGSP (Korea Good Supply Practice) ex post facto management to be implemented within this month but the domestic wholesaling industry opposes the plan on the gr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK